AzTrials
AzTrials

Right to Left ShuntPhase 3PFO DetectionNCT01773252

Right to Left Cardiac Shunt Detection

A Phase 3 study testing Flow Detection System in people with Right to Left Shunt and Patent Foramen Ovale, run by Cardiox Corporation at 8 sites in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The purpose of this study is to evaluate the sensitivity and specificity of the Cardiox Flow Detection System (FDS) in identifying an intracardiac right-to-left shunt (RLS) compared to the results of transesophageal echocardiography (TEE). Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Flow Detection System
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
141 participants
Where
8 sitesUnited States
Study dates
Nov 2012to Nov 2015
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • At least 18 years of age;
  • Is currently scheduled (within five days of FDS) for a TEE study with agitated saline contrast (bubble study) or has had a TEE procedure with agitated saline contrast study (bubble study) within the previous 12 months;
  • If the Subject has undergone a shunt closure procedure, the protocol related TEE must be conducted greater than 12 months post closure.
  • Is able to read and understand the ICF and has voluntarily provided written informed consent;
  • Subject is able to perform a successful Valsalva maneuver (obtaining a score of 3 stars) using the Cardiox FDS device.

Who cannot join

  • Subjects with known allergy or sensitivity to ICG or to iodide contrast dye or iodides including medications with high iodine content;
  • Pregnant women or nursing mothers;
  • Subjects scheduled for a radioactive iodine uptake studies (eg, thyroid studies) within one week of completing this study.

Trial locations and contacts

8 sites in 1 country.

8 sites in 1 country

United States8 sites
  • University of Colorado

    Aurora, Colorado, 80045

  • Tufts Medical Center

    Boston, Massachusetts, 02111

  • Rush University Medical Center

    Chicago, Illinois, 60612

  • Methodist DeBakey Heart and Vascular Center

    Houston, Texas, 77030

  • UCLA Medical Center

    Los Angeles, California, 90095

  • Columbia University Medical Center

    New York, New York, 10032

  • Heart and Vascular Center of Arizona

    Phoenix, Arizona, 85006

  • Swedish Medical Center

    Seattle, Washington, 98122

Other trials in United States

About this study

Official title: A With-in Subject, Controlled Study to Determine the Sensitivity and Specificity of the Cardiox Flow Detection System for the Detection of Right-to-Left Cardiac Shunts Compared to Transesophageal Echocardiography and Transcranial Doppler Ultrasound

The purpose of this study is to evaluate the sensitivity and specificity of the Cardiox Flow Detection System (FDS) in identifying an intracardiac right-to-left shunt (RLS) compared to the results of transesophageal echocardiography (TEE).

RLS intracardiac shunts are associated with a number of clinically important syndromes including paradoxical thromboembolism (causing stroke or other systemic infarct), migraine headaches (particularly with aura), desaturation with obstructive sleep apnea, and decompression illness. From a research perspective, the detection of shunts in subjects with these types of syndromes is critical in helping to define the role of RLS in these disease processes. From a clinical perspective, shunt detection will be increasingly important in an era where interventional procedures for repairing cardiac defects are available for subjects determined to be at risk.

Read more

The currently accepted reference standard for detection of an intra-cardiac patent foramen ovale/atrial septal defect (PFO/ASD) RLS is a transesophageal echocardiography (TEE), a procedure that is invasive, uncomfortable, and requires conscious sedation.

Alternative options include transthoracic echocardiography (TTE) with injection of agitated saline (with and without Valsalva strain), a procedure that is far less sensitive than TEE due to the echocardiography imaging limitations seen in many adults.

Finally, transcranial Doppler (TCD) with injection of agitated saline (with and without Valsalva strain) is a newer entrant into this arena that does not require sedation or any invasive instrumentation.

The Cardiox Model 100 FDS utilizes an optical sensor positioned on the surface of the subject's skin at the scaphoid fossa of the ear. Next, a predetermined dose of an indicator dye, indocyanine green (ICG), is injected at a predetermined rate into a peripheral antecubital vein of the subject while the subject performs a breathing maneuver called a Valsalva maneuver. The exhalation by the subject into a mouthpiece connected to a pressure transducer via a flexible tubing extension, or its equivalent (ie, performing the Valsalva maneuver), is an essential step for all existing RLS detection methods. The Valsalva maneuver by the subject creates a pressure differential between the right and left sides of the heart. This Valsalva maneuver results in blood flow from the right side of the heart to the left side of the heart through an ASD, and/or causes a PFO, if present, to open, also allowing blood to flow directly from the right side to the left side of the heart without passing through the lungs (pulmonary vasculature) for oxygenation.

The Earpads, including their fluorescence sensor arrays (FSA), are used to measure the relative concentration (ie, fluorescence signal level) of ICG dye in the bloodstream as a function of time. If a premature inflection or peak occurs in the ICG dye concentration level at a time point prior to the rise and fall of the concentration associated with the main bolus of indicator, then a RLS is present in the heart. The amplitude of this premature ICG dye-dilution curve (referred to as "RLS-indicator dilution curve") is used to subsequently quantify the magnitude of the right-to-left shunt by ratiometrically comparing the amplitude of this RLS indicator dilution curve to the amplitude of the main indicator dilution curve associated with that portion of the injected ICG dye that follows the normal pathway from the right side of the heart, through the lungs, and into the left side of the heart (referred to as "normal indicator dilution curve").

Being tested
Flow Detection System
Keywords
RLS, RTLS, PFO, ASD, shunt, cardiac, paradoxical thromboembolism, interventional cardiology, stroke, migraine, aura, obstructive sleep apnea, decompression illness, neurology, transesophageal echocardiography, TEE, transthoracic echocardiography, TTE, transcranial Doppler, ultrasound
Medical subject headings
Foramen Ovale, Patent, Heart Septal Defects, Atrial, Stroke, Migraine Disorders, Epilepsy, Sleep Apnea, Obstructive

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Flow Detection SystemDevice

    Also called Model 100

Study groups in NCT01773252
Study groupRoleWhat they receive
TEEExperimentalWithin patient comparison of TEE, FDS and a TCD from select study sites
Receives: Device: Flow Detection System

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Presence or absence of shunt

    To establish the sensitivity and specificity of the Cardiox FDS using transesophageal echocardiography (TEE) as the reference standard

    Measured: Five days

  2. Adverse Events

    To establish the safety of the Cardiox FDS device

    Measured: Five days

Secondary outcomes (1)
  1. Presence or absence of shunt

    To establish the positive percent agreement and the negative percent agreement of Cardiox FDS procedure with a transcranial Doppler (TCD) from select study sites.

    Measured: Three days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Jan 2013 (estimated)
  2. Study startNov 2012
  3. Primary completionOct 2015
  4. Study completionNov 2015

Why it stopped: Business decision to perform a market withdrawal of the product

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
141 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01773252
Sponsor's protocol ID
FDS-0005
Acronym
PFO Detection
Status last verified
Nov 2015
First submitted
8 Jan 2013
Last updated
13 Nov 2015
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Flow Detection System in people with Right to Left Shunt and Patent Foramen Ovale, run by Cardiox Corporation at 8 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 13 Nov 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 8 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was stopped early (reason given: Business decision to perform a market withdrawal of the product). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Presence or absence of shunt (time frame: Five days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Nov 2015.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in